Cargando…

Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review

BACKGROUND: BRCA1/2 mutation carriers are suggested with regular breast cancer surveillance screening strategies using mammography with supplementary MRI as an adjunct tool in Western countries. From a cost-effectiveness perspective, however, the benefits of screening modalities remain controversial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jiaxin, Jia, Ziqi, Zhang, Menglu, Liu, Gang, Xing, Zeyu, Wang, Xin, Huang, Xin, Feng, Kexin, Wu, Jiang, Wang, Wenyan, Wang, Jie, Liu, Jiaqi, Wang, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785233/ https://www.ncbi.nlm.nih.gov/pubmed/35083138 http://dx.doi.org/10.3389/fonc.2021.763161

Ejemplares similares

Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis
por: Jia, Ziqi, et al.
Publicado: (2021)

The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients With Germline Pathogenic Variants in Cancer Predisposition Genes
por: Liu, Jiaqi, et al.
Publicado: (2021)

Effects of Ulinastatin on Proliferation and Apoptosis of Breast Cancer Cells by Inhibiting the ERK Signaling Pathway
por: Xing, Zeyu, et al.
Publicado: (2021)

Effect of MiR-210 on the Chemosensitivity of Breast Cancer by Regulating JAK-STAT Signaling Pathway
por: Xing, Zeyu, et al.
Publicado: (2021)

Clinical Application and Feasibility of MRI-Guided Breast Biopsy of Breast Minimal Lesions in Chinese Population
por: Wang, Jie, et al.
Publicado: (2020)

Expression and prognostic value of CDK1, CCNA2, and CCNB1 gene clusters in human breast cancer
por: Xing, Zeyu, et al.
Publicado: (2021)

Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer
por: Huang, Xin, et al.
Publicado: (2020)

Overview on population screening for carriers with germline BRCA mutation in China
por: Lei, Huijun, et al.
Publicado: (2022)

CircRNA circ-PDCD11 promotes triple-negative breast cancer progression via enhancing aerobic glycolysis
por: Xing, Zeyu, et al.
Publicado: (2021)

Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers
por: Tommasi, Chiara, et al.
Publicado: (2021)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

Differences of Variable Number Tandem Repeats in XRCC5 Promoter Are Associated with Increased or Decreased Risk of Breast Cancer in BRCA Gene Mutation Carriers
por: Cui, Jian, et al.
Publicado: (2016)

The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy
por: Markowska, J., et al.
Publicado: (2013)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers
por: Lesueur, Fabienne, et al.
Publicado: (2018)

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

Case Report: Co-Existence of BRCA2 and PALB2 Germline Mutations in Familial Prostate Cancer With Solitary Lung Metastasis
por: Tang, Tang, et al.
Publicado: (2020)

Identifying clinicopathological risk factors for regional lymph node metastasis in Chinese patients with T1 breast cancer: a population-based study
por: Liu, Gang, et al.
Publicado: (2023)

Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation
por: Ramos, Marcelo Cristiano de Azevedo, et al.
Publicado: (2018)

Effect and Safety of Therapeutic Regimens for Patients With Germline BRCA Mutation-Associated Breast Cancer: A Network Meta-Analysis
por: Jiang, Ying, et al.
Publicado: (2021)

Automated diagnosis of pancreatic mucinous and serous cystic neoplasms with modality-fusion deep neural network using multi-modality MRIs
por: Zhang, Gong, et al.
Publicado: (2023)

Advanced Nano-Carriers for Anti-Tumor Drug Loading
por: Xiang, Jia, et al.
Publicado: (2021)

Management of the asymptomatic BRCA mutation carrier
por: Teller, Paige, et al.
Publicado: (2010)

DrABC: deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data
por: Liu, Jiaqi, et al.
Publicado: (2022)

Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review
por: Huber, D., et al.
Publicado: (2020)

Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers
por: Hamdi, Yosr, et al.
Publicado: (2021)

Breast cancer surveillance for BRCA1/2 mutation carriers – is “early detection” early enough?
por: Bernstein-Molho, Rinat, et al.
Publicado: (2019)

Case Report: Coinheritance of Germline Mutations in APC and BRCA1 in Colorectal Cancer
por: Huang, Wei, et al.
Publicado: (2021)

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers
por: Pataky, Reka, et al.
Publicado: (2013)

Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis
por: Michaan, Nadav, et al.
Publicado: (2021)

Cancer risks among BRCA1 and BRCA2 mutation carriers
por: Levy-Lahad, E, et al.
Publicado: (2007)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer
por: Ye, Fugui, et al.
Publicado: (2021)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Colorectal surveillance outcomes from an institutional longitudinal cohort of lynch syndrome carriers
por: del Carmen, Gabriel, et al.
Publicado: (2023)

Characterization of Synonymous BRCA1:c.132C>T as a Pathogenic Variant
por: Li, Jun, et al.
Publicado: (2022)

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
por: Li, Jun, et al.
Publicado: (2021)

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review
por: Huber, D., et al.
Publicado: (2021)

BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
por: Solano, Angela R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2a9ruvpvjqts3su06rnpqasinl